
NASDAQHealthcareMedical - Diagnostics & Research
Latest quote
$273.4
−$16.52 · -5.70%
Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.
Previous close
$273.4
−$16.52 · -5.70%
Regular session · ET · Market data may be delayed.
Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.
Day range
Current $273.4
52-week range
Current $273.4
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
65
Undervalued
Sentiment
47
Mixed
Risk
43
Elevated Risk
Momentum
69
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.
Day range
Current $273.4
52-week range
Current $273.4
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 2.31B USD | 1.7B USD | 1.08B USD | 820.22M USD | 625.49M USD |
| Cost of goods sold | 810.63M USD | 673.75M USD | 589.83M USD | 456.26M USD | 318.42M USD |
| Gross profit | 1.5B USD | 1.02B USD | 492.74M USD | 363.97M USD | 307.07M USD |
| Research and development | 624.11M USD | 404.14M USD | 320.68M USD | 316.42M USD | 264.21M USD |
| Selling, general, and administrative | 1.18B USD | 841.31M USD | 618.31M USD | 588.59M USD | 511.03M USD |
| Operating expenses | 1.81B USD | 1.25B USD | 938.99M USD | 905.01M USD | 775.24M USD |
| Interest income | 45.89M USD | 43.25M USD | 24.35M USD | 3.54M USD | 5.38M USD |
| Interest expense | 4.07M USD | 10.69M USD | 12.64M USD | 9.32M USD | 8.31M USD |
| Depreciation and amortization | 43.48M USD | 30.97M USD | 24.1M USD | 16.7M USD | 11.25M USD |
| Operating income | −309.91M USD | −222.29M USD | −446.25M USD | −541.04M USD | −468.17M USD |
| Net income | −208.16M USD | −190.43M USD | −434.8M USD | −547.8M USD | −471.72M USD |
Company facts updated Nov 22, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
Average target
$396.59
45.06% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI1.42B0.08%689.3B USD0.03%$340.02-3.52%
Vanguard Morningstar Small-Cap ETFVB1.27B0.70%78.7B USD0.03%$270.68-2.56%
Vanguard Morningstar Small-Cap Growth ETFVBK711.86M1.65%22.5B USD0.05%$298.35-3.85%
Vanguard Extended Market ETFVXF677.29M0.73%30.2B USD0.05%$211.44-3.21%
iShares Biotechnology ETFIBB303.55M2.83%10.53B USD0.44%$199.54-2.05%
ARK Innovation ETFARKK234.55M1.31%6.12B USD0.75%$64.22-6.83%
iShares Russell Mid-Cap Growth ETFIWP223.17M1.30%16.37B USD0.23%$116.81-4.32%
Vanguard Health Care ETFVHT173.14M0.73%20.8B USD0.09%$326.69-0.40%
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Morningstar Small-Cap ETFVB
Vanguard Morningstar Small-Cap Growth ETFVBK
Vanguard Extended Market ETFVXF
iShares Biotechnology ETFIBB
ARK Innovation ETFARKK
iShares Russell Mid-Cap Growth ETFIWP
Vanguard Health Care ETFVHTAI-generated and delayed market data for informational and educational purposes only. Not investment advice.